Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.27%
#2 MiL.k Alliance MiL.k Alliance +22.68%
#3 Biconomy Biconomy +20.40%
#4 The Black Bull The Black Bull +17.73%
#5 THORChain THORChain +17.53%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +16.51%
#7 Tutorial Tutorial +13.02%
#8 THORChain Yield THORChain Yield +12.99%
#9 XPIN Network XPIN Network +12.89%
#10 MetaDAO MetaDAO +12.86%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Classement en actions #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Prix de l'action
$58.70
Dernière synchronisation: 2024-01-23
Capitalisation boursière
$2.98B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Mirati Therapeutics, Inc. (MRTX)

Catégorie

Healthcare
EPS pour Mirati Therapeutics, Inc. (MRTX)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Mirati Therapeutics, Inc., l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Mirati Therapeutics, Inc. de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH